Advertisement

Topics

Novartis receives positive news in eye drug P3 studies

05:16 EDT 20 Jun 2017 | Pharmafile

Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it as effective as its nearest rival but needing fewer doses. The drug, if approved by the FDA, will be used in the treatment of neocascular age-related macular degeneration (nAMD).

read more

Original Article: Novartis receives positive news in eye drug P3 studies

NEXT ARTICLE

More From BioPortfolio on "Novartis receives positive news in eye drug P3 studies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...